Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pediatric Central Diabetes Insipidus due to Arginine Vasopressin Deficiency in the Perianesthetic Period.

Paediatric anaesthesiaยท2026
Same author

Use of Continuous Glucose Monitors in Publicly Insured Youth With Type 2 Diabetes: A 12-month Pilot and Feasibility Study.

Journal of diabetes science and technologyยท2025
Same author

Reassessing the routine histopathological evaluation of anastomotic doughnuts in colorectal procedures: A 10-year retrospective study.

Human pathologyยท2025
Same author

Mechanisms behind the LncRNAs-mediated regulation of paclitaxel (PTX) resistance in human malignancies.

Experimental cell researchยท2025
Same author

LncRNAs in modulating cancer cell resistance to paclitaxel (PTX) therapy.

Medical oncology (Northwood, London, England)ยท2024
Same author

Frequency and clinical characteristics of children and young people with type 2 diabetes at diagnosis from five world regions between 2012 and 2021: data from the SWEET Registry.

Diabetologiaยท2024

Related Experiment Video

Updated: Jun 5, 2026

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers
11:34

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers

Published on: December 5, 2017

Testing for HER2 in Breast Cancer: A Continuing Evolution.

Sejal Shah1, Beiyun Chen

  • 1Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA.

Pathology Research International
|December 29, 2010
PubMed
Summary
This summary is machine-generated.

Accurate human epidermal growth factor receptor 2 (HER2) testing is crucial for breast cancer management. This review covers HER2

More Related Videos

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells
08:28

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells

Published on: May 9, 2025

Related Experiment Videos

Last Updated: Jun 5, 2026

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers
11:34

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers

Published on: December 5, 2017

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells
08:28

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells

Published on: May 9, 2025

Area of Science:

  • Oncology
  • Molecular Biology
  • Immunology

Background:

  • Human epidermal growth factor receptor 2 (HER2) is a key prognostic and predictive factor in breast cancer.
  • HER2 overexpression occurs in 15%-20% of invasive breast carcinomas, correlating with poorer outcomes.
  • Trastuzumab targets HER2, making accurate HER2 assessment vital for treatment decisions in HER2-positive breast cancer.

Purpose of the Study:

  • To provide a comprehensive review of human epidermal growth factor receptor 2 (HER2).
  • To discuss HER2's discovery, biology, and clinical significance in breast cancer.
  • To cover prognostic value, targeted therapies, testing modalities, and interpretation guidelines.

Main Methods:

  • Literature review of HER2 discovery, biology, and clinical applications.
  • Analysis of prognostic and predictive roles of HER2 in breast cancer.
  • Review of current and emerging HER2 testing methodologies and interpretation standards.

Main Results:

  • HER2 status significantly impacts breast cancer prognosis and treatment response.
  • Trastuzumab is an effective targeted therapy for HER2-positive breast cancers.
  • Accurate HER2 assessment requires understanding various testing modalities and interpretation guidelines.

Conclusions:

  • Comprehensive understanding of HER2 is essential for optimal breast cancer management.
  • Accurate HER2 testing and interpretation are critical for guiding targeted therapy.
  • Ongoing research into new testing modalities will further refine HER2 assessment.